Offer - Urjas Oil for just ₹ 1 X
Clonam IR 0.25 Tablet MD is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Clonam IR 0.25 Tablet MD safe for pregnant women?
Pregnant women may experience moderate side effects from Clonam Ir. It is best to stop taking Clonam Ir immediately and inform your doctor if you notice any discomfort.
Is the use of Clonam IR 0.25 Tablet MD safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Clonam Ir. Immediately discontinue Clonam Ir if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Clonam IR 0.25 Tablet MD on the Kidneys?
Clonam Ir rarely harms the kidneys.
What is the effect of Clonam IR 0.25 Tablet MD on the Liver?
Side effects of Clonam Ir rarely affect the liver.
What is the effect of Clonam IR 0.25 Tablet MD on the Heart?
Clonam Ir is completely safe for the heart.
If you are suffering from any of the following diseases, you should not take Clonam IR 0.25 Tablet MD unless your doctor advises you to do so -
Is this Clonam IR 0.25 Tablet MD habit forming or addictive?
Yes, Clonam IR 0.25 Tablet MD can get addictive. Consume it only after doctor's advise.
Is it safe to drive or operate heavy machinery when consuming?
No, you should do not do anything that requires concentration and attention as the Clonam IR 0.25 Tablet MD can make you feel drowsy.
Is it safe?
Clonam IR 0.25 Tablet MD is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
Yes, Clonam IR 0.25 Tablet MD is useful in treating mental disorders.
Interaction between Food and Clonam IR 0.25 Tablet MD
Clonam IR 0.25 Tablet MD may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Clonam IR 0.25 Tablet MD
Consult your doctor before consuming alcohol while taking Clonam IR 0.25 Tablet MD as it can have severe side effects.
No, Clonam Ir does not cause weight gain. However, if you gain weight after taking Clonam Ir, discuss it with your doctor.
Yes, Clonam Ir causes withdrawal symptoms when the drug is discontinued. These withdrawal symptoms can include new or worsening seizures, hallucinating (seeing things or hearing voices that do not exist), changes in behavior, sweating, uncontrollable shaking of a part of your body, stomach or muscle cramps, anxiety, or difficulty falling asleep or staying asleep.
No, Clonam Ir, does not cause stomach upset. For mild stomach upset you are advised to eat light and non-spicy meals along with this drug initially. But if you are experiencing severe stomach upset after taking this medicine then inform your doctor immediately.
Yes, Clonam Ir causes erectile dysfunction because of its effects on endocrine gland. If you experience erectile dysfunction after taking it, do not stop the drug without consulting your doctor. Discuss with your doctor, he/she will provide you solutions or prescribe alternative medicines.
Ideally Clonam Ir can be taken with food or without food post evening because its absorption is not affected by food. However, you are recommended to take it as per doctor's instructions.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Klonopin (clonazepam)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 418
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 330-332